Obesity and Pediatric Multiple Sclerosis

Pediatric MS subjects will meet below inclusion and Who Should NOT Join This Trial: Who May Qualify: - Ability to provide willing to sign a consent form (or assent for minors) - Relapsing-remitting MS diagnosis per 2017 McDonald criteria - Ages ≥ 10 years to ≤ 20 years - Diagnosis of MS or first clinical symptom of MS (whichever comes first) within ≤ 36 months from the time of enrollment. Who Should NOT Join This Trial: - Progressive form of MS - Patients with an active, chronic disease of the immune system other than MS - Conditions affecting the central nervous system (CNS) white matter (e.g. leukodystrophy) or for whom another condition may better explain imaging abnormalities (e.g. lupus) - Myelin oligodendrocyte glycoprotein (MOG) antibodies on serologic testing - Corticosteroid exposure within 30 days of study enrollment Control subjects (Aim 2) will meet the below inclusion and Who Should NOT Join This Trial: Who May Qualify: - Ability to provide willing to sign a consent form (or assent for minors) - Age-, sex-, \& BMI-matched to pediatric MS subjects (1:1 allocation) - Healthy children and young adults from the local communities Who Should NOT Join This Trial: - History of past imaging or neurologic event raising concern for any inflammatory CNS process - Medical history or previous/current diagnosis consistent with an autoimmune disorder pertaining to any system of the body (e.g. diabetes mellitus type 1, Crohn's disease, lupus) Always talk to your doctor about whether this trial is right for you.